Dr. Clara Hoebart leads ChanPharm's cardiotoxicity team, overseeing hiPSC-derived cardiomyocyte models and cardiac safety studies. She manages cell culture workflows and ensures high-quality preparations for MEA and patch clamp-based cardiotoxicity profiling.